Biomarkers, erectile dysfunction, and cardiovascular risk prediction:the latest of an evolving concept
基本信息来源于合作网站,原文需代理用户跳转至来源网站获取
摘要:
A number of circulating and imaging biomarkers are robustly associated with cardiovascular (CV) risk. The overall expectation from a biomarker in the erectile dysfunction (ED) setting is to enhance the optimal management of a man with this disorder but no clinical atherosclerosis. Evidence demonstrating that these biomarkers enhance risk prediction for individuals with ED is at this stage still limited for most of them. A better identification of the subsets of the ED population that require further risk stratification, as well as the initiation of randomized trials that will formally test the ability of biomarkers to predict CV risk, could make biomarker?guided prevention an attainable goal.